PT-141 (Bremelanotide): Mechanism, Reconstitution & Research Use

PT-141 (bremelanotide) is a cyclic heptapeptide analogue of alpha-MSH that activates melanocortin receptors MC3R and MC4R in the hypothalamus, and is studied in research settings for its role in central sexual-arousal pathways. Unlike PDE5 inhibitors, it acts on brain signalling rather than peripheral blood flow, which is the core distinction researchers are usually trying to understand when they search for it.

Bremelanotide is one of the few compounds in this category with an actual regulatory approval pathway: the FDA approved it in 2019 as Vyleesi for hypoactive sexual desire disorder (HSDD) in premenopausal women. That approval history is relevant context for researchers, though it does not extend to other populations or uses being investigated in ongoing research.

What Is PT-141?

PT-141 is studied for engaging the central dopaminergic reward circuitry that governs sexual motivation, rather than acting on vascular tissue. MC4R activation in the medial preoptic area is linked to increased dopamine release in the nucleus accumbens and recruitment of oxytocin neurons in the paraventricular nucleus, a pathway studied for increasing desire itself rather than only the physical response to stimulation (Diamond et al., 2019, Obstet Gynecol; Hadley & Dorr, 2003, Ann N Y Acad Sci).

Full mechanism detail and citations are available on the PT-141 product page.

PT-141 vs. PDE5 Inhibitors: Two Different Pathways

This is the mechanistic distinction most searched around PT-141:

	PDE5 Inhibitors (sildenafil, tadalafil)	PT-141 (bremelanotide)
Site of action	Peripheral — vascular smooth muscle	Central — hypothalamus (MC4R)
Mechanism	Increases cGMP, promotes vasodilation	Activates dopaminergic reward circuitry
Requires stimulation	Yes	No
What it targets	Physical response / blood flow	Desire / motivation

Research on MC4R signalling and sexual function has characterised this central mechanism in more detail (Van der Ploeg et al., 2006, J Sex Med).

MC3R and MC4R: Different Roles

MC4R is considered the primary mediator of PT-141’s studied effects on sexual behaviour, and MC4R knockout models show markedly reduced sexual behaviour, underscoring the receptor’s role. MC4R also regulates energy homeostasis, which is why mild appetite-related effects are sometimes noted in research discussions. MC3R, expressed more in limbic circuitry, is studied for a possible contribution to anxiolytic effects, though its role is less characterised than MC4R’s.

Reconstitution for Research Use

PT-141 is supplied as a lyophilised powder and reconstituted with bacteriostatic water before use in a research setting:

Reconstitution: add bacteriostatic water to the vial, swirl gently until fully dissolved, do not shake. Storage after reconstitution: keep refrigerated (2-8°C), protect from light, and use within 30 days.

Milo-Lab supplies PT-141 as a 10mg vial, with a certificate of analysis per batch, formulated for subcutaneous administration in research settings, the same delivery route studied in the original clinical trial programme. Some compounded nasal-spray formulations exist commercially elsewhere, but the injectable vial is the format with the underlying trial data behind it.

Regulatory Context

The Phase 3 RECONNECT trial programme behind the 2019 FDA approval enrolled 1,267 premenopausal women with HSDD, with satisfying sexual events and distress scores as primary endpoints; both showed significant improvement versus placebo at the approved 1.75mg subcutaneous dose. That trial population and approved indication are specific and narrow, and should not be read as validating other uses under investigation in ongoing research, including in male subjects, where earlier Phase II work also reported effects on erectile function and desire before development was redirected toward the HSDD indication.

Researchers working on related central-pathway compounds may also be interested in the Sexual Health category, which groups PT-141 alongside other peptides studied in this space.

Research Use Only

PT-141 (bremelanotide) supplied by Milo-Lab is sold strictly for laboratory research use. While it carries an FDA-approved indication as Vyleesi for HSDD, the vials sold here are unbranded research-grade material intended for qualified researchers, not for human self-administration outside a clinical context. Nothing in this article is medical advice or a treatment recommendation.

See the full PT-141 profile for pack details, FAQs and complete study citations.